Tilray Medical

INFARMED has authorized Tilray Medical’s quality control laboratory in Cantanhede to perform on-site microbiological and physicochemical tests. The approval enables faster releases, lower testing costs and reduces reliance on third-party providers. Tilray thereby strengthens Cantanhede as a strategic hub for cultivation, production and supply of medical cannabis to regulated markets such as Germany, the United Kingdom, Poland and Italy. » More on finanzen.net

Tilray Medical regards the recent classification by the KBV and the GKV-Spitzenverband on prescribing full‑spectrum extracts in standardized quality as an important step forward for clinical practice and patient access. The company is calling for a legal clarification to ensure long‑term legal certainty for doctors, patients, providers and payers and to make therapy and reimbursement pathways predictable. Tilray emphasizes the importance of freedom of therapy, continuity of care and broad access to high‑quality cannabis medicines, and offers its production and supply infrastructure to support the transition. Tilray holds around a 45 percent market share in Germany for medical cannabis extracts and says it is able to help shape further development of the supply framework. » More on finanzen.net

Tilray Medical Deutschland has announced the launch of ARX, a locally developed premium brand for medical cannabis grown at the Aphria RX facility in Neumünster to EU‑GMP standards. ARX is based on strains from Broken Coast’s gene bank and combines Canadian breeding know‑how with German production and national distribution via CC Pharma and 14U Pharma. The brand will be presented at Mary Jane Berlin 2026 and aims to deliver greater consistency, supply security and long‑term access for patients and healthcare professionals. » More on finanzen.net